Drug therapy: Fenoldopam - A selective peripheral dopamine-receptor agonist for the treatment of severe hypertension

New England Journal of Medicine

Volumn 345, Issue 21, 2001, Pages 1548-1557

  Murphy, Michael B ^a,b   Murray, Clare ^a   Shorten, George D ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b University College Cork and INFANT Centre   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIGOXIN; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR; ENALAPRIL; ESMOLOL; FENOLDOPAM MESILATE; LOSARTAN; NICARDIPINE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; PARACETAMOL; ANTIHYPERTENSIVE AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FENOLDOPAM;

ANTIHYPERTENSIVE ACTIVITY; CLINICAL TRIAL; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG INFUSION; DRUG MECHANISM; DRUG POTENTIATION; FIRST AID; HUMAN; HYPERTENSION; HYPOTENSION; MEAN ARTERIAL PRESSURE; NAUSEA AND VOMITING; NONHUMAN; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; TACHYCARDIA; UNITED STATES; VASODILATATION; ANIMAL; BLOOD PRESSURE; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOPAMINE AGONISTS; DRUG SYNERGISM; FENOLDOPAM; HUMANS; HYPERTENSION; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; PERIOPERATIVE CARE; RECEPTORS, DOPAMINE;

EID: 0035936042     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra010253     Document Type: Review

References (93)

1. Clinical presentation and management of patients with uncontrolled, severe hypertension: Results from a public teaching hospital
2. Hypertensive emergencies
3. Esmolol: A review of its therapeutic efficacy and pharmacokinetic characteristics
4. Neuromuscular interactions between mivacurium and esmolol in rabbits
5. Comparative pharmacokinetics of nicardipine hydrochloride, a new vasodilator, in various species
6. Decrease in vecuronium infusion dose requirements by nicardipine in humans
7. Interactions between nicardipine and enflurane, isoflurane, and sevoflurane
8. Decay of nitroprusside. II. In vivo
9. Hypotensive and vasodilator drugs
10. Local cerebral blood flow and the electrocorticogram during sodium nitroprusside hypotension
11. Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopaminel-receptor agonist, in hypertensive patients
12. Prolonged fenoldopam infusions in patients with mild to moderate hypertension: Pharmacodynamic and pharmacokinetic effects
13. Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension
14. Effects of several monoamine oxidase inhibitors on the cardiovascular actions of naturally occurring amines in the dog
15. The renal dopamine receptors
16. Model systems for the study of seven-transmembrane-segment receptors
17. Multiple receptors for dopamine
18. Molecular biology of dopamine receptors
19. The pharmacological basis of the clinical use of dopamine
20. Dopamine receptors and hypertension: Physiologic and pharmacologic implications
21. Tubuloglomerular feedback and blood flow autoregulation during DA1-induced renal vasodilation
22. In vivo venodilator action of fenoldopam, a dopamine D(1)-receptor agonist
23. Renal and endocrine effects of fenoldopam and metoclopramide in normal man
24. Selective dopamine-1 receptor stimulation produces natriuresis by a direct tubular action
25. Evidence that specific dopamine-1 receptor activation is involved in dopamine-induced renin release
26. Dopamine attenuates the contractile response to angiotensin II in isolated rat glomeruli and cultured mesangial cells
27. Dopaminergic stimulation of c-AMP accumulation in cultured rat mesangial cells
28. Effects of selective dopamine-1 receptor activation on intraocular pressure in man
29. Characterization of dopamine receptor subtypes involved in experimentally induced gastric and duodenal ulcers in rats
30. The effect of selective dopamine-1 receptor stimulation on renal and adrenal function in man
31. The inhibition of ganglionic transmission via presynaptic dopamine DA1 and postsynaptic DA2 receptor activation in the canine cardiac sympathetic ganglia
32. Dopamine agonists both stimulate and inhibit prolactin release in GH4ZR7 cells
33. The emetic effect of B-HT 920 and apomorphine in the dog: Antagonism by haloperidol
34. Inhibition of proximal tubule Na(+)-K(+)-ATPase activity requires simultaneous activation of DA1 and DA2 receptors
35. Prostaglandin E2 production in rat IMCD cells. I. Stimulation by dopamine
36. Involvement of dopamine receptor subtypes in dopaminergic modulation of aldosterone secretion in rats
37. Cardiovascular dopamine receptors: Physiological, pharmacological and therapeutic implications
38. Dopamine inhibits Na(+)-H+ exchanger activity in renal BBMV by stimulation of adenylate cyclase
39. Hormonal interactions with the proximal Na(+)-H+ exchanger
40. ANP inhibits Na(+)-H+ antiport in proximal tubular brush border membrane: Role of dopamine
41. Phosphorylated Mr 32,000 dopamine- and cAMP-regulated phosphoprotein inhibits Na+,K(+)-ATPase activity in renal tubule cells
42. Quantitative importance of changes in postglomerular colloid osmotic pressure in mediating glomerulotubular balance in the rat
43. Dopamine
44. Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist
45. Pharmacokinetic evaluations of fenoldopam following intravenous infusion and oral administration in elderly patients with congestive heart failure
46. 1 agonist, fenoldopam
47. Sustained hemodynamic effects of the selective dopamine-1 agonist, fenoldopam, during 48-hour infusions in hypertensive patients: A dose-tolerability study
48. A retrospective analysis of fenoldopam renal excretion in 65 subjects: Evidence for possible intrarenal formation of fenoldopam from its metabolites
49. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure
50. Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension
51. Selective peripheral dopamine-1 receptor stimulation with fenoldopam in human essential hypertension
52. Studies with fenoldopam, a dopamine receptor DA1 agonist, in essential hypertension
53. Cardiovascular and renal profile of acute peripheral dopaminel-receptor agonism with fenoldopam
54. Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood pressure reduction by intravenous administration of the dopaminel agonist fenoldopam
55. Randomized, prospective trial of fenoldopam vs sodium nitroprusside in the treatment of acute severe hypertension
56. Delayed recovery of renal function in patients with acute renal failure due to accelerated hypertension
57. Transient and sustained recovery from renal shutdown in accelerated hypertension
58. Intravenous fenoldopam versus sodium nitroprusside in patients with severe hypertension
59. Fenoldopam, a dopamine agonist, for hypertensive emergency: A multicenter randomized trial
60. Risk of myocardial ischaemia during anesthesia in treated and untreated hypertensive patients
61. Control of tachycardia and hypertension following coronary artery bypass graft surgery: Efficacy and haemodynamic effects of esmolol
62. Enoximone vs nicardipine during the early postoperative course of patients undergoing cardiac surgery: A prospective study of two therapeutic strategies
63. Fenoldopam infusion for the treatment of postoperative hypertension
64. A comparison of fenoldopam and nitroprusside in the control of hypertension following coronary artery surgery
65. 1-receptor stimulation by fenoldopam in the treatment of postcardiac surgical hypertension
66. Fenoldopam: A review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies
67. Hydrallazine (Apresoline) hydrochloride: Pharmacological observations and clinical results in the therapy of hypertension
68. Minoxidil: A review of its pharmacological properties and therapeutic use
69. The pharmacology of verapamil. III. Pharmacokinetics in normal subjects after intravenous drug administration
70. Electrocardiographic changes during acute treatment of hypertensive emergencies with sodium nitroprusside or fenoldopam
71. Intraocular pressure increases with fenoldopam, but not nitroprusside, in hypertensive humans
72. Fenoldopam, a selective dopamine-1 receptor agonist, raises intraocular pressure in males with normal intraocular pressure
73. Effect of intravenous fenoldopam on intraocular pressure in ocular hypertension
74. The effect of acetaminophen on the disposition of fenoldopam: Competition for sulfation
75. Interaction study of fenoldopam - Digoxin in congestive heart failure
76. Intrarenally produced angiotensin II opposes the natriuretic action of the dopamine-1 receptor agonist fenoldopam in rats
77. Potentiation by enalaprilat of fenoldopamevoked natriuresis is due to blockade of intrarenal production of angiotensin-II in rats
78. Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure?
79. "Renal-dose" dopamine for the treatment of acute renal failure: Scientific rationale, experimental studies and clinical trials
80. Renal-dose (low-dose) dopamine for the treatment of sepsis-related and other forms of acute renal failure: Ineffective and probably dangerous
81. Prevention and complete reversal of cyclosporine A-induced renal vasoconstriction and nephrotoxicity in the rat by fenoldopam
82. Attenuation of amphotericin B nephrotoxicity in the dog by the fenoldopam prodrug, SK&F R-105058
83. The effect of fenoldopam on the acute and subacute nephrotoxicity produced by amphotericin B in the dog
84. Mechanisms of amphotericin B-induced reduction of the glomerular filtration rate: A micropuncture study
85. Renal hemodynamics in radiocontrast medium-induced renal dysfunction: A role for dopamine receptors
86. Fenoldopam reverses cyclosporine-induced renal vasoconstriction in kidney transplant recipients
87. Fenoldopam improves renal hemodynamics impaired by positive end-expiratory pressure
88. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects
89. Renal protection and improved outcome by utilization of a DA-1 agonist (fenoldopam) in TAAA repair